Skip to content

LSD: all studies

Page 185 of 282: studies 1,841 to 1,850 of 2,815, newest first. Back to the LSD overview

Research

Embracing Change: Impermanence Acceptance Mediates Differences in Death Processing Between Ayahuasca Users and Non-users

July 28, 2024 Jonathan David, Aviva Berkovich-Ohana, Yair Dor-Ziderman 2 citations preprint

Background: How the human psyche interacts with the theme of death is fundamental to individual and societal life, profoundly influencing cognition, affect, and behavior. Death-related psychological phenomena, such as death anxiety and acceptance, have been shown in clinical studies to be influenced by psychedelic (LSD and psilocybin) interventions. However, the literature lacks a comprehensive...

A Comparative Model of Mysticism: Cognitive Neuroscience, Phenomenal Experiences, and Noetic Accounts

Archive for the Psychology of Religion July 26, 2024 Hemal P. Trivedi 2 citations

This article proposes a model of comparative mysticism that bases its rationale for comparison in the dynamic interaction between three components: neurocognitive mechanisms and substrates, phenomenal experiences, and noetic accounts. In examining the phenomenon of ego - dissolution ( EDn ), using this model, a scholar can identify universal and contextual components of a mystic’s experiences....

Exploring Legal Frameworks for the Clinical Use of Psychedelic Substances in Mental Health Treatment

July 25, 2024 Anggraeni Endah Kusumaningrum, Ardianto Sucinta

In recent years, interest in the use of psychedelic substances in the treatment of mental disorders has increased significantly. Recent research shows the potential of psychedelic substances such as psilocybin, LSD, and MDMA to treat disorders such as major depression, post-traumatic stress disorder (PTSD), and substance addiction. However, the clinical use of psychedelic substances remains...

DOI: 10.56444/ulrev.v8i2.5241 (opens in new tab) Full text (opens in new tab) Psychedelic therapy Psilocybin treatment Psychedelic medicine Innovative therapy +17

Toxicology and Pharmacological Interactions of Classic Psychedelics.

Current Topics in Behavioral Neurosciences July 24, 2024 Kelan Thomas 3 citations

As psychedelics are being investigated for more medical indications, it has become important to characterize the adverse effects and pharmacological interactions with these medications. This chapter will summarize what is known about the toxicology and drug-drug interactions for classic psychedelics, such as LSD, psilocybin, DMT, 5-MeO-DMT, mescaline, 2C-B, Bromo-DragonFLY, and 25X-NBOMe.

DOI: 10.1007/7854_2024_508 (opens in new tab) Full text (opens in new tab) Drug safety toxicology Adverse effects Drug–drug interactions Psychedelics hallucinogens +5

Psychedelic trip sitting, dosages and intensities: Supplementing clinical studies with anecdotal reports

Journal of Psychedelic Studies July 17, 2024 Liam Engel, Sascha Thal, Stephen Bright et al. 4 citations

Abstract Background and aims Online communities provide insights into psychedelic consumption, assisting in identification of trends, informing both harm reduction provisions and clinical research. This study extracts forum data on psychedelic substances, dosages, and administration routes, categorising and analysing self-reported consumption to inform care services and guide clinical work with...

Psychedelic experiences and long-term spiritual growth: a systematic review

Current Psychology July 12, 2024 William A. Schutt, Julie J. Exline, Kathleen C. Pait et al. 25 citations

Abstract Psychedelic substances, which can occasion mystical experiences, are sometimes used for religious and spiritual reasons. Despite strong links between psychedelics and spirituality, no previous systematic review has investigated connections between psychedelics and indicators of long-term spiritual growth. Thus, 34 empirical studies were analyzed with 19,724 total participants from 32...

Psychothérapie assistée par psychédéliques (PAP) : le modèle genevois

Annales Médico-psychologiques revue psychiatrique July 10, 2024 Federico Seragnoli, Gabriel Thorens, Louise Penzenstadler et al. 8 citations

Dans cet article, nous avons pour objectif de décrire un modèle interdisciplinaire de psychothérapie assistée par psychédéliques (PAP) que nous avons développé dans un cadre institutionnel aux hôpitaux universitaires de Genève. La psychothérapie assistée par psychédéliques (PAP) est une approche psychothérapeutique exploitant l’altération de l’état de conscience induite par une substance...

A lasting impact of serotonergic psychedelics on visual processing and behavior

bioRxiv (Cold Spring Harbor Laboratory) July 6, 2024 Chloe L. West, Georgia Bastos, Annabel Duran et al. 2 citations preprint

Abstract Serotonergic psychedelics (e.g., psilocybin) have shown potential for treating psychiatric disorders, with therapeutic effects lasting weeks after a single dose. Predictive processing theories posit that psychedelics work by loosening priors or high-level beliefs, including ingrained biases that have become pathological, leading to shifts in bottom-up vs top-down information processing...

Exploring the Impact of Recreational Drugs on Suicidal Behavior: A Narrative Review

Psychoactives July 3, 2024 Rosa María Moret, Sergio Sanz‐gómez, Santiago Gascón et al. 4 citations

Substance use/abuse and suicide are two closely related phenomena, mostly due to neurobiological, psychological, and social impairments. In the present narrative review, the relationship between suicidal behavior (SB) and the use and abuse of common recreational drugs, such as alcohol, cannabis, cocaine, methamphetamine, heroin, nicotine, ketamine, psilocybin, MDMA, and LSD, has been explored....

Early-onset alcohol, tobacco, and illicit drug use with age at onset of hypertension: a survival analysis.

Social Psychiatry and Psychiatric Epidemiology July 1, 2024 Kesheng Wang, Saima Shafique, Nianyang Wang et al. 1 citation

To examine the associations of age when first substance use and early-onset substance use before age 18 with age at onset (AAO) of hypertension. This study included 19,270 individuals with AAO of hypertension from the 2015-2019 National Survey on Drug Use and Health. Age when first use of 10 substance use variables included alcohol, daily cigarettes, cigars, smokeless tobacco, marijuana,...

DOI: 10.1007/s00127-023-02596-9 (opens in new tab) Full text (opens in new tab) Substance abuse Adolescent health Age at onset Cox regression +6